| Size | Price | |
|---|---|---|
| 5mg | ||
| 10mg | ||
| Other Sizes |
| ln Vivo |
Kidney cancer models can be created in animals by using ferric nitrilotriacetate.
|
|---|---|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Although NTA concentrations decrease rapidly after cessation of intake, small amounts of NTA remain in the bones after each administration… /triacetic acid/ Oral administration of NTA-(14)C to rats. 95% is excreted in the urine. Less than 1%… is excreted as CO2. NTA absorption from the gastrointestinal tract varies: dogs absorb more than rats, and rats absorb more than rabbits and monkeys. …Deposited in the bones. Concentration…increases with increasing administration frequency. The most active accumulation areas are located in sites of high bone formation. /NTA/ Transferrin is completely saturated after injection of large amounts of iron triacetic acid. Most of the excess serum Fe3+-nta exists in the form of bound serum proteins, rather than as free Fe3+-nta. Intracellularly, Fe2+ is converted to Fe3+ in ferritin, which is only absorbed during physiological cellular “exhaustion.” In the blood, iron can be rapidly oxidized to Fe3+ by dissolved oxygen, which then binds to a specific iron transporter, β1-globulin. |
| References |
|
| Additional Infomation |
Mechanism of Action
This study investigated the acute nephrotoxicity mechanism of iron chelates in vivo. Intraperitoneal injection of the nephrotoxic ferrous hypozinotriacetate (Fe-NTA) (15 mg Fe/kg body weight) led to the selective loss of a 17 kDa renal protein. N-terminal sequence analysis confirmed that the 16 N-terminal residues of this 17 kDa protein were identical to those of renal fatty acid-binding protein (k-FABP), a proteolytically modified form of α2U-globulin (the major protein in the urine of adult male rats). Immunochemical studies using an anti-α2U-globulin polyclonal antibody confirmed that a single injection of Fe-NTA resulted in a decrease in k-FABP levels. However, a 19 kDa protein identical to α2U-globulin gradually appeared in the kidney, indicating that Fe-NTA treatment inhibited the proteolytic processing of α2U-globulin in the proximal tubules of the kidney. Monitoring of k-FABP and its precursor α2U globulin confirmed that repeated exposure to Fe-NTA inhibited both renal proteolytic and endocytic activities. Therapeutic Use Experimental Use: Adding more than 100 ppm of extra iron (in the form of ferrous hyponitroglycerin) to the diet of chicks infected with Salmonella strain 9 significantly improved chick survival. Experimental Use: Appropriate application of ferrous hyponitroglycerin complex should be effective in treating iron deficiency anemia. |
| Molecular Formula |
C6H6FENO6
|
|---|---|
| Molecular Weight |
243.96
|
| Exact Mass |
243.954
|
| CAS # |
16448-54-7
|
| PubChem CID |
27880
|
| Appearance |
Light yellow to yellow solid powder
|
| Boiling Point |
498.2ºC at 760mmHg
|
| Flash Point |
255.1ºC
|
| Vapour Pressure |
2.78E-11mmHg at 25°C
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
171
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Fe+3].O=C(CN(CC([O-])=O)CC([O-])=O)[O-]
|
| InChi Key |
FXDLIMJMHVKXAR-UHFFFAOYSA-K
|
| InChi Code |
InChI=1S/C6H9NO6.Fe/c8-4(9)1-7(2-5(10)11)3-6(12)13;/h1-3H2,(H,8,9)(H,10,11)(H,12,13);/q;+3/p-3
|
| Chemical Name |
2-[bis(carboxylatomethyl)amino]acetate;iron(3+)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0990 mL | 20.4952 mL | 40.9903 mL | |
| 5 mM | 0.8198 mL | 4.0990 mL | 8.1981 mL | |
| 10 mM | 0.4099 mL | 2.0495 mL | 4.0990 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
